Toxicities of targeted therapy and their management in kidney cancer

European Urology

Volumn 59, Issue 4, 2011, Pages 526-540

  Di Lorenzo, Giuseppe ^a   Porta, Camillo ^b   Bellmunt, Joaquim ^c   Sternberg, Cora ^d   Kirkali, Ziya ^e   Staehler, Michael ^f   Joniau, Steven ^g   Montorsi, Francesco ^h   Buonerba, Carlo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c HOSPITAL DEL MAR   (Spain)

^d SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^e DOKUZ EYLUL UNIVERSITY   (Turkey)

^f UNIVERSITY OF MUNICH   (Germany)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Metastatic renal cell cancer; Targeted agents; Toxicity

Indexed keywords

ACARBOSE; AMLODIPINE; ANTIANEMIC AGENT; ATENOLOL; ATORVASTATIN; BEVACIZUMAB; COLESTYRAMINE; EVEROLIMUS; GEMFIBROZIL; GLIMEPIRIDE; GLITAZONE DERIVATIVE; HYDROCHLOROTHIAZIDE; INTERFERON; LAMIVUDINE; LAROPIPRANT PLUS NICOTINIC ACID; LISINOPRIL; LOSARTAN; METFORMIN; METHYLPHENIDATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PAZOPANIB; PIOGLITAZONE; RECOMBINANT ERYTHROPOIETIN; SITAGLIPTIN; SORAFENIB; SPIRONOLACTONE; SUNITINIB; TEMSIROLIMUS; THYROID HORMONE; UNINDEXED DRUG;

ANEMIA; ANGINA PECTORIS; ANOREXIA; ARTICLE; ASPERGILLOSIS; BLEEDING; BONE MARROW TOXICITY; CANCER GRADING; CANCER INCIDENCE; CANDIDIASIS; COGNITIVE THERAPY; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG ERUPTION; DYSPNEA; EMBOLISM; EXERCISE; FATIGUE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEART LEFT VENTRICLE FUNCTION; HEPATITIS B; HUMAN; HYPERAMYLASEMIA; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERCREATININEMIA; HYPERGLYCEMIA; HYPERLIPASEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; IMMUNE DEFICIENCY; INFECTION; INFECTION RISK; INTERSTITIAL PNEUMONIA; IRON DEFICIENCY; KIDNEY CARCINOMA; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; LYMPHOCYTOPENIA; MASSAGE; METABOLIC DISORDER; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHYSICAL ACTIVITY; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; REHABILITATION CARE; SIDE EFFECT; SKIN TOXICITY; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOSIS; VIRUS REACTIVATION; VOMITING;

EID: 79952282127     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.01.002     Document Type: Review

References (69)

1. G. Di Lorenzo, R. Autorino, and C.N. Sternberg Metastatic renal cell carcinoma: recent advances in the targeted therapy era Eur Urol 56 2009 959 971
2. G. Di Lorenzo, C. Buonerba, and M. Biglietto The therapy of kidney cancer with biomolecular drugs Cancer Treat Rev 36S3 2010 S16 20
3. N. Bhojani, C. Jeldres, and J.-J. Patard Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma Eur Urol 53 2008 917 930
4. NCCN clinical practice guidelines in oncology: Cancer-related fatigue. National Comprehensive Cancer Network Web site. http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp.
5. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.
6. G. Mancia, G. De Backer, and A. Dominiczak 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur Heart J 28 2007 1462 1536
7. L. Rydén, E. Standl, and M. Bartnik Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur Heart J 28 2007 88 136 (Pubitemid 46137814)
8. Sutent [package insert]. New York, NY: Pfizer.
9. Nexavar [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals.
10. Avastin [package insert]. South San Francisco, CA: Genentech.
11. Afinitor [package insert]. East Hanover, NJ: Novartis Pharmaceuticals.
12. Torisel [package insert]. New York, NY: Pfizer.
13. Votrient [package insert]. Philadelphia, PA: GlaxoSmithKline.
14. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124 (Pubitemid 46089672)
15. R.J. Motzer, T.E. Hutson, and P. Tomczak Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
16. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134 (Pubitemid 46089673)
17. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 2009 3312 3318
18. B. Escudier, J. Bellmunt, and S. Négrier Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J Clin Oncol 28 2010 2144 2150
19. B. Escudier, A. Pluzanska, and P. Koralewski Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103 2111 (Pubitemid 350296300)
20. B.I. Rini, S. Halabi, and J.E. Rosenberg Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 J Clin Oncol 28 2010 2137 2143
21. B.I. Rini, S. Halabi, and J.E. Rosenberg Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 J Clin Oncol 26 2008 5422 5428
22. R.J. Motzer, B. Escudier, and S. Oudard Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 2010 4256 4265
23. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
24. G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma New Engl J Med 356 2007 2271 2281 (Pubitemid 46849157)
25. C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
26. M.E. Gore, C. Szczylik, and C. Porta Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial Lancet Oncol 10 2009 757 763
27. W.M. Stadler, R.A. Figlin, and D.F. McDermott Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America Cancer 116 2010 1272 1280
28. S. Antoun, L. Birdsell, M.B. Sawyer, P. Venner, B. Escudier, and V.E. Baracos Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study J Clin Oncol 28 2010 1054 1060
29. B.I. Rini, I. Tamaskar, and P. Shaheen Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib J Natl Cancer Inst 99 2007 81 83
30. P. Wolter, C. Stefan, and B. Decallonne The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation Br J Cancer 99 2008 448 454
31. X. Zhu, K. Stergiopoulos, and S. Wu Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis Acta Oncol 48 2009 9 17
32. S. Wu, J.J. Chen, A. Kudelka, J. Lu, and X. Zhu Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis Lancet Oncol 9 2008 117 123
33. V. Ranpura, B. Pulipati, D. Chu, X. Zhu, and S. Wu Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis Am J Hypertens 23 2010 460 468
34. V. Ranpura, S. Hapani, J. Chuang, and S. Wu Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials Acta Oncol 49 2010 287 297
35. S.R. Nalluri, D. Chu, R. Keresztes, X. Zhu, and S. Wu Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis JAMA 300 2008 2277 2285
36. A.F. Sher, D. Chu, and S. Wu Risk of bleeding in cancer patients treated with the angiogenesis inhibitor bevacizumab: a meta-analysis J Clin Oncol 27 2009 15s
37. T.K. Choueiri, F.A. Schutz, Y. Je, J.E. Rosenberg, and J. Bellmunt Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials J Clin Oncol 28 2010 2280 2285
38. Y. Je, F.A. Schutz, and T.K. Choueiri Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials Lancet Oncol 10 2009 967 974
39. D. Pouessel, and S. Culine High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor Eur Urol 53 2008 376 381 (Pubitemid 350296582)
40. G. Di Lorenzo, R. Autorino, and G. Bruni Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis Ann Oncol 20 2009 1535 1542
41. D.A. White, P. Camus, and M. Endo Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma Am J Respir Crit Care Med 182 2010 396 403
42. S. Hapani, D. Chu, and S. Wu Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis Lancet Oncol 10 2009 559 568
43. X. Zhu, S. Wu, W.L. Dahut, and C.R. Parikh Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis Am J Kidney Dis 49 2007 186 193 (Pubitemid 46178407)
44. J. Autier, B. Escudier, J. Wechsler, A. Spatz, and C. Robert Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor Arch Dermatol 144 2008 886 892 (Pubitemid 352039741)
45. D. Chu, M.E. Lacouture, T. Fillos, and S. Wu Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis Acta Oncol 47 2008 176 186
46. G. Di Lorenzo, G. Carten, and R. Autorino Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer J Clin Oncol 27 2009 4469 4474
47. J.A. Garcia, T.E. Hutson, and P. Elson Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab Cancer 116 2010 5383 5390
48. G. Di Lorenzo, C. Buonerba, and P. Federico Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma Eur Urol 58 2010 906 911
49. M.J. Mackenzie, B.I. Rini, and P. Elson Temsirolimus in VEGF-refractory metastatic renal cell carcinoma Ann Oncol 22 2011 145 148
50. R.M. Bukowski, W.M. Stadler, and D.F. McDermott Safety and efficacy of sorafenib in elderly patients treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program Oncology 78 2010 340 347
51. T. Eisen, S. Oudard, and C. Szczylik Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial J Natl Cancer Inst 100 2008 1454 1463
52. V. Margulis, S.F. Matin, and N. Tannir Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma J Urol 180 2008 94 98
53. E. Jonasch, C.G. Wood, and S.F. Matin Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 4076 4081
54. T. Powles, I. Kayani, and C.U. Blank The safety and efficacy of sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer [abstract] J Clin Oncol 28 2010 15s
55. C.L. Cowey, C. Amin, and R.S. Pruthi Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma J Clin Oncol 28 2010 1502 1507
56. O. Minton, A. Richardson, M. Sharpe, M. Hotopf, and P. Stone A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue J Natl Cancer Inst 100 2008 1155 1166
57. B. Melichar, P. Koralewski, and A. Ravaud First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma Ann Oncol 19 2008 1470 1476
58. H. Miyake, T. Kurahashi, and K. Yamanaka Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation Urol Oncol 28 2010 515 519
59. M. Schmidinger, C.C. Zielinski, and U.M. Vogl Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 26 2008 5204 5212
60. Bellmunt J, Eisen T, Fishman M, Qinn D. Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol. In press. doi:10.1016/j. critrevonc.2010.03.006.
61. A. Macci, C. Madeddu, G. Gramignano, C. Mulas, E. Sanna, and G. Mantovani Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study Oncologist 15 2010 894 902
62. P.A. Clavien, J. Barkun, and M.L. de Oliveira The Clavien-Dindo classification of surgical complications: five-year experience Ann Surg 250 2009 187 196
63. G. Khan, A. Golshayan, and P. Elson Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency Ann Oncol 21 2010 1618 1622
64. S. Ruppin, C. Protzel, K.-J. Klebingat, and O.W. Hakenberg Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure Eur Urol 55 2009 986 988
65. N. Garnier-Viougeat, O. Rixe, and G. Paintaud Pharmacokinetics of bevacizumab in haemodialysis Nephrol Dial Transplant 22 2007 975
66. C. Porta, J. Bellmunt, T. Eisen, C. Szczylik, and P. Mulders Treating the individual: the need for a patient-focused approach to the management of renal cell carcinoma Cancer Treat Rev 36 2010 16 23
67. G. Mancia, S. Laurent, and E. Agabiti-Rosei Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document J Hypertens 27 2009 2121 2158
68. Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC). National Cancer Institute Web site. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc.htm. Updated 9 August 2010.
69. P450 drug interaction table. Indiana University School of Medicine Division of Clinical Pharmacology Web site. http://medicine.iupui.edu/clinpharm/ ddis/table.asp. Accesse 21 November 2010.